Перейти к основному содержимому
Madrigal

Associate Director, API Quality Assurance (GMP)

УдалённоUnited States только
Опубликовано
Опыт
Синьор
Занятость
Полная занятость
Размер компании
Средняя
$169k–$198k/yr
Проверьте доступность

Доступно для: US only. Укажите, откуда вы работаете, чтобы проверить доступность.

Коротко по делу

Senior API Quality Assurance leader for GMP external manufacturing oversight. 10–12+ years GMP/API experience with CMO/CDMO management, ICH Q7 expertise, and inspection readiness. Remote within the US (must work with US regulatory/benefits context).

Ключевые навыки

API qualityICH Q7

Обязательные навыки

GMPICH Q8ICH Q9ICH Q10ICH Q11FDAEMAVeeva Vault Qualitydeviation/CAPAchange controlbatch record reviewquality agreementstech transfervalidationquality metrics

Желательные навыки

MS/PhDexperience with small molecule API manufacturingexperience with oligonucleotide manufacturingexperience in pharmaceutical/biotech external manufacturing networks

Чем предстоит заниматься

  • Own GMP API Quality Assurance strategy, governance cadence, and standards across external API manufacturers
  • Lead quality oversight of API and intermediate manufacturing at CMOs/CDMOs, ensuring ICH Q7 and global GMP compliance
  • Set expectations for API batch record review quality, documentation rigor, and decision rationale traceability
  • Drive deviation impact assessment, RCA rigor, CAPA linkage, and effectiveness verification for API quality events
  • Oversee change control review and approval for API processes, specifications, methods, and partner-initiated changes
  • Maintain quality agreements with API CMOs and lead performance governance routines (KPIs, scorecards, QBRs)
  • Partner with MSAT/CMC on API control strategy evolution, validation readiness, and tech transfer to/from partners
  • Ensure quality oversight across the API lifecycle, including PPQ, routine manufacturing, and post-approval changes
  • Lead inspection readiness for API operations, including documentation, evidence packages, and audit response narratives
  • Support FDA, EMA, and other health authority inspections related to API manufacturing and partner audits
  • Drive trending and recurrence prevention for API quality events; deliver management review-ready insights
  • Lead and mentor API QA staff and provide quality input on cross-functional governance forums

Что требуется

  • BS or MSc in a scientific discipline (Chemistry, Chemical Engineering, Pharmacy, or related)
  • 10-12 years of GMP pharmaceutical/biotech experience with significant focus on API quality and CMO oversight
  • Demonstrated leadership in API batch disposition, deviation/CAPA, and change control governance
  • Strong knowledge of ICH Q7, ICH Q8-Q11, FDA, EMA, and global API regulatory expectations
  • Proven track record managing external API manufacturers and supporting health authority inspections

Преимущества

  • Base pay, bonus and equity (equity for all employees)
  • Comprehensive benefits including flexible paid time off, medical, dental, vision and life/disability insurance
  • 401(k) offerings (traditional, Roth, and employer match)
  • Additional voluntary benefits like supplemental life insurance and legal services
  • Mental health benefits through Employee Assistance Program for employees and their family
  • Reasonable accommodations for individuals with disabilities during hiring process

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).

BiopharmaСредняя
$169k–$198k/yr